Anticancer Drugs and the Kidney

Genome-wide CRISPR Screen Reveal Targets of Chiral Gold(I) Anticancer Compound in Mammalian Cells

“…The development of efficacious transition-metal anticancer drugs is highly attractive yet a challenging goal in drug discovery. Platinum agents are first-line chemotherapy for several cancer types and are primordial to the development of improved metallodrugs. − However, toxic side effects and acquired tumor resistance to platinum therapy are major drawbacks. − Alternative efforts to develop other transition-metal-based anticancer agents such as Co, Ti, , Ru, Os, , and Au − have been stymied by unexplained cytotoxicity, rapid deactivation, poor pharmacokinetics, and poor in vivo potency . Gold-based compounds have been applied as potent anticancer drug candidates in preclinical and clinical trials with great promise. − Recently, the FDA approved gold drug auranofin, used for the treatment of rheumatoid arthritis, was repurposed as an anticancer agent with promising outcomes .…”

“…Platinum agents are first-line chemotherapy for several cancer types and are primordial to the development of improved metallodrugs. 1 − 3 However, toxic side effects and acquired tumor resistance to platinum therapy are major drawbacks. 4 − 7 Alternative efforts to develop other transition-metal-based anticancer agents such as Co, 8 Ti, 9 , 10 Ru, 11 Os, 12 , 13 and Au 14 − 16 have been stymied by unexplained cytotoxicity, rapid deactivation, poor pharmacokinetics, and poor in vivo potency.…”